§MHT Eligibility Criteria Group: Laura Baquedano, Joaquín Calaf, Mª Jesús Cancelo, Antonio Cano, Camil Castelo Branco, Rafael Comino, Pluvio Coronado, Ester de la Viuda, José Luis Doval, Maria Fasero, Javier Ferrer, Gabriel Fiol, Ana Gómez, Mª Ángeles Gómez, Silvia González, Misericordia Guinot, Eva Iglesias, Ana Rosa Jurado, Plácido Llaneza, Iñaki Lete, Paloma Lobo, Dani Lubián, Montserrat Manubens, Milagros Martínez, Marina Mazheika, Nicolás Mendoza, Aníbal Nieto, Laura Nieto, Borja Otero, Santiago Palacios, María Jesús Plá, Ezequiel Pérez-Campos, Jesús Presa, Francisco Quereda, Isabel Ramírez, Miriam Ribes, Beatriz Roca, Sonia Sánchez, Rafael Sánchez-Borrego, Ana Santaballa.
The data collected during the last two decades on the effects of menopausal hormone therapy (MHT) could help to provide a safer and more effective long term-treatment of menopause symptoms and possible complications such as osteoporotic fractures, cognitive impairment, or cardiovascular conditions, as well as an improved quality of life. Having a history of suffering from gynecological cancer (endometrial, cervical or ovarian) is one of the conditions that most strongly determines the use of any form of MHT due to the concerns associated with a possible recurrence of the disease. Objective: To create a set of eligibility criteria for the use of MHT in gynecological cancer patients. Methods: The study was registered in PROSPERO (registration number CRD42020166658). Results: Ovarian cancer survivors who use MHT have better overall survival, disease-free survival, and lower recurrence rates than women survivors who do not use MHT. Endometrial cancer survivors who use MHT do not have a higher rate of disease recurrence than those survivors who do not use MHT. Cervical cancer survivors who use MHT do not have a higher rate of disease recurrence than those survivors who do not use MHT. Conclusion: MHT is safe in women who have suffered from most of non-advanced gynecological cancers.